Author of

• 11692

  +

  P2.10 - Poster Session 2 - Chemotherapy (ID 207)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11724

    +

    P2.10-032 - Palliative chemotherapy of lung cancer in elderly : single center experiences (ID 2061)

    09:30 - 09:30  |  Author(s): J. Jo
    • Abstract

    Background
    Elderly patients with cancer are significantly under-represented in all clinical trials, including those for lung cancer. However, there is a general agreement that age alone cannot be the only parameter to be taken into consideration for decision making. We investigated feasibility and efficacy of palliative chemotherapy for elderly patients with lung cancer.

    Methods
    We reviewed medical record based on database of Jeju National University Hospital. Between January,2007, and December,2012, Elderly patients (aged 70 or more) with lung cancer who began to receive palliative chemotherapy were 28 persons. Progression-free survival(PFS) and overall survival(OS) in terms of Non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) were investigated respectively.

    Results
    Median age of patients were 75 year-old (range, 70-82) and 20 patients were male. 20 patients were non-small cell lung cancer and eight patients were small cell lung cancer. In overall patients, median PFS of 1st line palliative chemotherapy and median OS were 5.0 months (95% confidence interval[CI], 4.43-9.86 months) and 18 months (95% CI, 14.99-26.80 months), respectively. In NSCLC patients, mPFS was 5.0months (95% CI, 3.77-11.23 months) and mOS was 21.5 months (95% CI, 16.63-31.21 months).In SCLC patients mPFS and mOS were 5.5 months (95% CI, 2.97-9.53 months) and 11.0 months (95% CI, 3.46-23.04 months), respectively. 19 patients with NSCLC received sequential second line chemotherapy after progresssion. median number of chemotherapy regimen they received after progression was 1 (range, 1-6, 95% CI, 0.90-2.40). There was no significant difference of survival between age group of 70-74, 75-79 and more than 80.

    Conclusion
    Palliative chemotherapy for elerly patients with lung cancer is feasible. Even patients aged more than 70 would expect similar survival benefit compared to younger patients.